Streetbeat News

Stock Prices

CHTR

Charter Communications Inc (NASDAQ:CHTR) reported better-than-expected Q2 2024 financial results, with revenue and EPS surpassing analyst estimates. Despite losing residential Internet and video customers, the stock gained 16.6%. Analysts have raised their price targets for the stock.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 12:39 pm

AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) presented positive Phase 2b/3 study results for its Alzheimer's candidate, blarcamesine (ANAVEX2-73), showing significant slowing of disease progression. The stock is up 11.40% in premarket trading.

Portfolio Pulse from Vandana Singh

July 29, 2024 | 12:39 pm

CZWI

Citizens Community (NASDAQ:CZWI) reported Q2 2024 adjusted earnings per share (EPS) of $0.35, surpassing the analyst consensus estimate of $0.27 by 29.63%.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:36 pm

NRXP

NRx Pharmaceuticals announced that a Utah arbitrator denied Streeterville Capital's petition to prevent the spinoff of 49% of HOPE Therapeutics shares to NRx shareholders and to stop NRx from selling additional shares. The spinoff aims to provide value to NRx shareholders and potentially list HOPE Therapeutics on a national exchange.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:36 pm

TSLA

Tesla's Cybertruck lead engineer Wes Morrill announced that the range extender for the Cybertruck will be structurally mounted for safety reasons. The extender, an additional battery pack, will not be removable by owners. Tesla aims to ramp up Cybertruck production to 250,000 units annually by 2025, with current weekly production at 1,300 units. The company sold 8,755 Cybertrucks in the last quarter, surpassing Ford's F-150 Lightning sales.

Portfolio Pulse from Anan Ashraf

July 29, 2024 | 12:36 pm

L

Loews shares are trading higher following Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:36 pm

LGVN

Longeveron Inc (NASDAQ: LGVN) presented positive Phase 2a clinical trial data for its Alzheimer's treatment, Lomecel-B, at the Alzheimer's Association International Conference. The trial met its primary safety and secondary efficacy endpoints, showing potential in slowing disease progression and improving cognitive and functional outcomes. The FDA recently granted RMAT designation to Lomecel-B. LGVN stock is up 22.10% in premarket trading.

Portfolio Pulse from Vandana Singh

July 29, 2024 | 12:35 pm

NDAQ

Nasdaq, Inc. (NDAQ) announced the pricing of a secondary offering of 41,604,207 shares at $65.30 per share by Argus Seller, LP, an affiliate of Thoma Bravo, L.P. The offering is expected to close on July 30, 2024. Nasdaq will not receive any proceeds from this sale. Additionally, Nasdaq will repurchase 1,200,000 shares from the Selling Stockholder as part of its existing share repurchase program.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:34 pm

DIS

IMAX

Disney/Marvel's Deadpool & Wolverine sets IMAX records with a $36.5M global debut, achieving the biggest R-rated and July opening, the eighth biggest IMAX opening ever, and the biggest since Avatar: The Way of Water.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:34 pm

BMRC

COLB

HIG

KEY

ZION

Five financial stocks, Columbia Banking System Inc (COLB), Hartford Financial Services Group Inc (HIG), KeyCorp (KEY), Zions Bancorporation (ZION), and Bank of Marin Bancorp (BMRC), are identified as potentially overbought with high RSI values, indicating a possible short-term price decline.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 12:33 pm